NCT04085523: A trial that was reported late by Ascendis Pharma A/S
This trial has reported, although it was 91 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04085523 |
|---|---|
| Title | ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 24, 2020 |
| Completion date | Sept. 27, 2022 |
| Required reporting date | Sept. 27, 2023, midnight |
| Actual reporting date | Dec. 27, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 91 |